Aardvark Therapeutics, Inc. Common Stock (AARD) vs Lucid Diagnostics Inc. (LUCD)
A side-by-side comparison of Aardvark Therapeutics, Inc. Common Stock and Lucid Diagnostics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AARD
Aardvark Therapeutics, Inc. Common Stock
$4.98HealthcareDelayed quote: Oct 6, 2026, 11:04 AM EDT
LUCD
Lucid Diagnostics Inc.
$0.60HealthcareDelayed quote: Oct 6, 2026, 11:00 AM EDT
Total return — AARD vs LUCD
growth of $100 · dividends reinvested · last 2yAARD -63.5% (-39.6%/yr)LUCD -56.4% (-34.0%/yr)LUCD compounded faster over this window
AARD LUCD
AARD vs LUCD: by the numbers
- •LUCD is the larger company ($114M vs $109M market cap).
- •Both run net losses; AARD's is the smaller (0.00% vs -959.76% net margin).
Metrics side by side
Valuation
| Metric | AARD | LUCD |
|---|---|---|
| P/S ratio | N/A | 21.01 |
| P/B ratio | 1.46 | 10.47 |
Profitability
| Metric | AARD | LUCD |
|---|---|---|
| Gross margin | 0.00% | -60.26% |
| Operating margin | 0.00% | -1054.82% |
| Net margin | 0.00% | -959.76% |
| ROE | -93.44% | -478.26% |
| ROIC | -97.99% | -145.10% |
Go deeper
Dig into the metrics
Aardvark Therapeutics, Inc. Common Stock ROELucid Diagnostics ROEAardvark Therapeutics, Inc. Common Stock operating marginLucid Diagnostics operating marginAardvark Therapeutics, Inc. Common Stock revenue growthLucid Diagnostics revenue growthAardvark Therapeutics, Inc. Common Stock free cash flowLucid Diagnostics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.